Immatics N.V. Ordinary Shares (IMTX)
Immatics N.V. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company specializes in T-cell receptor (TCR) therapies, aiming to harness the immune system to target and destroy tumor cells. Based in Germany, Immatics advances personalized medicine approaches through its proprietary technological platform to identify and develop targeted treatments for various cancers.
Company News
Immatics N.V. announced the appointment of Venkat Ramanan, Ph.D. as its new Chief Financial Officer, replacing Arnd Christ. Dr. Ramanan brings over 25 years of biopharmaceutical finance experience from companies like Seagen, Gilead Sciences, and Amgen.
U.S. stocks closed higher on Tuesday as investors digested the key inflation data that heightened worries regarding inflation.
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock...
Investors liked what they heard in Immatics' interim results for experimental immunotherapy IMA203.